Stirling takes over Canadian plant

Australia's Stirling Products has acquired a pharmaceutical manufacturing facility in Cape Breton, Canada, purchased "at a major discount" to its $20 million going-concern replacement value. The deal follows the collapse of an unnamed Canadian pharmaceutical group and its institutional lender.

The cGMP-compliant facility is operational, and Stirling plans to take possession this week. The company cites the purchase as in line with its global positioning strategy. An industry press report says that Stirling may use the facility for third-party contract manufacturing of generic drugs, funded research, and drug production.

The facility is fitted with lab and drug manufacturing and packaging equipment. It includes water filtration systems, auto-mixing units to 3,000-kg capacity, and automated filling, labeling and packaging lines. Annual capacity is reportedly 550 million tablets, 5 million bottles and blend up to 1.5 million kg of product. It also has a granulating and grinding capacity.

- read the article

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.